- Home
- HBT vs MNMD Comparison
HBT vs MNMD Comparison
Compare HBT & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- MNMD
- Stock Information
- Founded
- HBT 1920
- MNMD 2019
- Country
- HBT United States
- MNMD United States
- Employees
- HBT N/A
- MNMD N/A
- Industry
- HBT Major Banks
- MNMD Pharmaceuticals and Biotechnology
- Sector
- HBT Finance
- MNMD Health Care
- Exchange
- HBT Nasdaq
- MNMD Nasdaq
- Market Cap
- HBT 812.0M
- MNMD 709.9M
- IPO Year
- HBT 2019
- MNMD N/A
- Fundamental
- Price
- HBT $25.80
- MNMD $9.57
- Analyst Decision
- HBT Buy
- MNMD Strong Buy
- Analyst Count
- HBT 5
- MNMD 7
- Target Price
- HBT $29.00
- MNMD $24.71
- AVG Volume (30 Days)
- HBT 22.3K
- MNMD 1.1M
- Earning Date
- HBT 10-20-2025
- MNMD 11-06-2025
- Dividend Yield
- HBT 3.32%
- MNMD N/A
- EPS Growth
- HBT 8.10
- MNMD N/A
- EPS
- HBT 2.42
- MNMD N/A
- Revenue
- HBT $229,851,000.00
- MNMD N/A
- Revenue This Year
- HBT $8.86
- MNMD N/A
- Revenue Next Year
- HBT $2.52
- MNMD N/A
- P/E Ratio
- HBT $10.46
- MNMD N/A
- Revenue Growth
- HBT 4.61
- MNMD N/A
- 52 Week Low
- HBT $19.46
- MNMD $4.70
- 52 Week High
- HBT $27.02
- MNMD $11.02
- Technical
- Relative Strength Index (RSI)
- HBT 50.84
- MNMD 51.80
- Support Level
- HBT $24.49
- MNMD $8.70
- Resistance Level
- HBT $26.43
- MNMD $9.95
- Average True Range (ATR)
- HBT 0.62
- MNMD 0.52
- MACD
- HBT -0.11
- MNMD -0.01
- Stochastic Oscillator
- HBT 51.84
- MNMD 54.37
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).